AbCellera shares jump after the company reports positive early clinical results for a treatment aimed at reducing hot flashes in menopausal women. The drug, ABCL635, is tested in a small study of about 80 participants and shows improvements compared with a placebo.
According to the reports, participants taking ABCL635 experience a significant reduction in the frequency and severity of hot flashes. One outlet describes the results as unusually strong, while another focuses on outcomes among women who initially report moderate to severe symptoms. Both accounts say the trial data show benefits over placebo, though details such as long-term outcomes, safety findings, and the size of the effect are described more generally across the coverage.
The outlets differ mainly in emphasis: one highlights the magnitude of the results, and the other highlights the specific subgroup of women with moderate or severe hot flashes. Both connect the news to a sharp increase in AbCellera’s stock price following publication of the trial findings.
